首页> 外文期刊>The Surgeon >Current treatments for axillary hyperhidrosis
【24h】

Current treatments for axillary hyperhidrosis

机译:腋窝多汗症的当前治疗方法

获取原文
获取原文并翻译 | 示例
       

摘要

Primary hyperhidrosis affects up to 1% of the population and has a significant negative impact on quality of life. It affects the axillae in approximately 80% of cases. Hyperhidrosis results from excessive sympathetic stimulation of the eccrine sweat glands: the various treatment modalities available target points along the pathway between the central nervous system and the peripheral gland. The first line of treatment is topical aluminium chloride, which is effective in the majority of cases. Alternative treatments such as systemic anti-cholinergics and iontophoresis have significant disadvantages, while surgical sympathectomy has been regarded as the gold-standard in treatment of this condition. Recently, attention has focused on the use of intradermal botulinum toxin for the treatment of axillary hyperhidrosis. This is a highly effective, minimally-invasive treatment with few side effects, and is now recommended as the treatment of choice in isolated axillary hyperhidrosis.
机译:原发性多汗症影响多达1%的人口,并对生活质量产生重大负面影响。在大约80%的情况下,它会影响腋窝。多汗症是由对内分泌汗腺的过度交感刺激引起的:各种可用的治疗方式可沿中枢神经系统与周围腺体之间的通路靶向。一线治疗是局部氯化铝,在大多数情况下有效。全身性抗胆碱能药和离子电渗疗法等替代疗法具有明显的缺点,而外科交感神经切除术已被视为治疗该病的金标准。最近,注意力集中在皮内肉毒杆菌毒素用于腋窝多汗症的治疗中。这是一种高效,微创的治疗方法,几乎​​没有副作用,现在推荐作为孤立的腋窝多汗症的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号